MINNEAPOLIS--(BUSINESS WIRE)--April 26, 2006--Urologix®, Inc. (NASDAQ:ULGX - News), today reported financial results for the fiscal third quarter and nine months ended March 31, 2006. Revenue for the third quarter of fiscal 2006 was $6.6 million, compared to $6.5 million in the same period of fiscal 2005. Treatment catheter sales, including revenue from Cooled ThermoTherapy(TM) mobile treatments, accounted for over 97% of revenue in the just completed quarter, up from 94% in the prior year period. Net earnings for the current quarter were $364,000 or $0.03 per diluted share, including $291,000 of equity-based compensation expense, compared to $686,000 or $0.05 per diluted share, for the third quarter of fiscal 2005. Fiscal 2005 results did not include any equity-based compensation expense.
